331 related articles for article (PubMed ID: 38332411)
1. Management of Hypertension in the Asia-Pacific Region: A Structured Review.
Rahman ARA; Magno JDA; Cai J; Han M; Lee HY; Nair T; Narayan O; Panyapat J; Van Minh H; Khurana R
Am J Cardiovasc Drugs; 2024 Mar; 24(2):141-170. PubMed ID: 38332411
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S; Volpe M
Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
[TBL] [Abstract][Full Text] [Related]
3. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of Combination of Renin-Angiotensin-Aldosterone System Inhibitors on Central Aortic Blood Pressure: A Cross-Sectional Observational Study in Hypertensive Outpatients.
Pradhan A; Vishwakarma P; Bhandari M; Sethi R; Narain VS
Cardiovasc Ther; 2020; 2020():4349612. PubMed ID: 32983258
[TBL] [Abstract][Full Text] [Related]
5. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
6. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
7. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.
Pongpanich P; Pitakpaiboonkul P; Takkavatakarn K; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Int Urol Nephrol; 2018 Dec; 50(12):2261-2278. PubMed ID: 30324578
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
9. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
10. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
[TBL] [Abstract][Full Text] [Related]
11. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
14. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.
Alcocer LA; Bryce A; De Padua Brasil D; Lara J; Cortes JM; Quesada D; Rodriguez P
Am J Cardiovasc Drugs; 2023 Nov; 23(6):663-682. PubMed ID: 37668854
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
16. Cochrane in context: pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
[TBL] [Abstract][Full Text] [Related]
17. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH; Hall AS
Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
19. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?
Kaiser EA; Lotze U; Schäfer HH
Clin Interv Aging; 2014; 9():459-75. PubMed ID: 24711696
[TBL] [Abstract][Full Text] [Related]
20. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]